Time course of imaging changes of GBM during extended bevacizumab treatment
暂无分享,去创建一个
Albert Lai | Whitney B. Pope | T. Cloughesy | W. Pope | P. Nghiemphu | A. Lai | S. Ananthnarayan | Timothy Cloughesy | Phioanh Nghiemphu | Suchitra Ananthnarayan | Jennie Bahng | James Roring | James Roring | J. Bahng | Suchitra Ananthnarayan
[1] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[2] P. Box. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2005 .
[3] P. Therasse,et al. Evaluation of response: new and standard criteria. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[5] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[6] S. Horvath,et al. Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 , 2007, Clinical Cancer Research.
[7] Tracy T Batchelor,et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. , 2006, Neuro-oncology.
[8] D. Gillespie,et al. Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas , 2006, Journal of Neuro-Oncology.
[9] Ucla Medical. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006 .
[10] H. Mehdorn,et al. Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.
[11] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[12] T. Cloughesy,et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen , 2003, Cancer.
[13] P. Korkolopoulou,et al. Hypoxia‐inducible factor 1α/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis , 2004, Neuropathology and applied neurobiology.
[14] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[15] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Gillespie,et al. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. , 2006, Journal of neuro-oncology.
[17] J. Smirniotopoulos,et al. Glioblastoma multiforme: radiologic-pathologic correlation. , 1996, Radiographics : a review publication of the Radiological Society of North America, Inc.
[18] A G Sorensen,et al. Comparison of diameter and perimeter methods for tumor volume calculation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Daniel J Brat,et al. 'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.
[20] Bradley J Erickson,et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. , 2006, Neuro-oncology.
[21] M J Gleason,et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Tracy T Batchelor,et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. , 2007, Trends in molecular medicine.
[23] V. Levin,et al. Effect of bevacizumab on radiation necrosis of the brain. , 2007, International journal of radiation oncology, biology, physics.
[24] Paul S Mischel,et al. MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.
[25] Fang Tan,et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.